Renowned Speakers

We’ve invited the top most influential speakers from around the world to give inspirational talks and lead practical workshops.

Dr. Joanne Sadier

University of Abu Dhabi University ,UAE United Arab Emirates

Biography

Dr. Richard Anderson

University of Ottawa, Canada Canada

Dr. Julia Fagen

University of North Carolina School of Medicine, USA USA

Dr. Robert Felix

Anglia Ruskin University, UK UK

Sophie Martin

University of Nantes France France

Rafaela Souza

Federal University of Pernambuco Brazil Brazil

Dr Ankur Joshi

Associate Professor Modern Institute of Pharmaceutical Sciences Indore, India Research Scholar Mandsaur University. India

Biography

Conference Information

Welcome Message

On behalf of the organizing committee, we cordially invite all of the leading scientists, academicians, researchers, Business delegates, exhibitors, sponsors and students from all over the world to attend the 15^th International Conference on Dementia and Dementia Care on November 23-25, 2023 happening on the beautiful city of London, UK

Dementia care 2023 has been thoughtfully planned to meet the expectations of our attendees and thus shares an insight into the recent research and cutting edge technologies, which gains immense interest and provides ideal setting for an interactive gathering of information.

Our aim is to explain the untouched science behind the mystery of Dementia 2023, their mechanism, diagnosis, treatment and management as well as to engage in a lively discussion on current breakthroughs in the field of dementia.

Participate in Dementia Care 2023 and join us to see the incredible gathering on Dementia Care.

We hope to see you soon at London.

The aim of the Conference:

Provide a platform for international relationships among the researchers involved in Dementia
To highlight, with talks and dialogue, the current questionable issues in the field
To refresh all sub-disciplines in the field of Dementia.
To discuss and examine innovative ideas by providing a platform for the speakers and audience interactions
To foster and conduct collaborative interdisciplinary research in state-of-the-art methodologies and technologies within its areas of expertise.
Opportunity to meet with plenary speakers, the world-leading thinkers, and innovators in the field.
Provide a conducive environment for the participants to share experiences.
Provide opportunities to form partnerships among research participants

Market Analysis

The Global market for Dementia medications is anticipated to develop as a result of the rising number of dementia patients and significant investments in drug research. The Neuroscience 2023 Association estimates that in 2018, there were about 5.7 million Americans with dementia. The global market for dementia pharmaceuticals is anticipated to develop as a result of both an increase in the number of dementia patients globally and higher player expenditure on pharmacological R&D activities.

The World Health Organization estimates that 50 million individuals worldwide suffer from dementia, with roughly 10 million new cases being identified year. Government and non-governmental groups are taking more actions to create a platform for the care of dementia sufferers. The Global Dementia Observatory was established by the World Health Organization in 2017 to facilitate monitoring and information sharing regarding legislation, service provision, epidemiology, and research related to dementia.

Target market growth is predicted to rise as big players approach developing nations to establish their corporate footprint. In addition, strategic cooperation between domestic and foreign businesses is anticipated to assist regional market expansion. AstraZeneca, Biogen Pharmaceuticals, Eli Lilly and Company, Eisai, Inc., F. Hoffmann-La Roche, Forest Laboratories, Inc., Janssen Pharmaceuticals, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Teva Pharmaceuticals Industries Ltd., and Valeant Pharmaceutical International are a few of the top dementia drug manufacturers in the market.

After multiple testing has been considered, the average yearly direct out-of-pocket costs in Austria range from EUR 253 (95% CI: -17 to 522) to EUR 859 (95% CI: -587 to 2306) but are not statistically significant. Before multiple testing correction, the average yearly hours of informal care that can be linked to dementia in Austria range between 163 (95% CI: 27-299) and 1051 (95% CI: 15-2086) annual hours and are statistically significant. The market for dementia care treatments is expanding as a result of the rising prevalence of dementia. The market for dementia treatments will expand as a result of therapeutic improvements and the creation of novel therapies for dementia 2023. Additionally, the susceptible ageing population may be seen as a boon to the expansion of this sector.

The market for neuroscience drugs is projected to rise as a result of the ageing population suffering from a variety of ailments and the rising prevalence of target conditions. The increasing incidence of dementia cases is one of the main factors influencing the global market for drugs to treat it. The increasing incidence of dementia cases is one of the main factors influencing the global market for drugs to treat it. Alzheimer's Disease International estimates that there will be more than 50 million dementia sufferers worldwide in 2020. This population is anticipated to double every 20 years, rising to 82 million in 2030 and 152 million in 2050.

The Dementia Care market under evaluation is anticipated to grow at significant rates throughout the projected period as a result of increased R&D activities in the development of efficient medications. Additionally, it is anticipated that the industry's growth will be accelerated by increased government spending in target disease care, support, and research. On the other hand, it is anticipated that the failure of investigational candidates in the late phases of development may stall market growth. According to a third-party data monitoring committee, Merck & Co., Inc. stopped investigating verubecestat, a potential treatment for Alzheimer's, in February 2017 because the Phase II/III research appeared to be failing.

In 2022, the market for dementia care goods will likely be worth US$27 million. The market is anticipated to grow at a CAGR of 6.9% from 2022 to 2032, reaching US$ 56.2 million. The market for dementia care goods is always expanding significantly, which can be attributable to greater illness management knowledge, improved sales opportunities, technological advancements, and enhancements to already existing technologies.

Globally increasing dementia incidences create a market potential for Neurological care goods. More than 10 million new instances of dementia are reported annually globally, according to the World Alzheimer Report 2015, suggesting a sizable global market for these dementia care solutions. Europe ranks second in terms of revenue, accounting for almost 31.3% of the market for dementia care goods. The market is anticipated to grow strongly over the course of the projected period due to increased disposable income and consumer tendencies for products related to healthcare.

Treatments for dementia and mobility disorders were valued at $10.5 billion globally in 2011, and are anticipated to reach $11.1 billion globally in 2012. After growing at a five-year compound annual growth rate (CAGR) of 8.5%, the total market value is anticipated to reach $16.7 billion in 2017. Treatments for progressive dementia are anticipated to increase in value from $7.3 billion in 2012 to around $11 billion in 2017, or a CAGR of 8.4%. In order to treat progressive dementia, sales of Alzheimer's medications are anticipated to reach $5.1 billion in 2012 and roughly $7.7 billion in 2017, representing a CAGR of 8.6%.

In the seven largest markets, the market for vascular dementia is anticipated to grow at a roughly 4.05% compound annual growth rate (CAGR) from 2019 to 2032, from USD 2,230 million in 2021 to a sizeable market by 2032. The anticipated release of new treatments could grow the market in the upcoming years, helped along by a rise in the number of people with vascular dementia who have been diagnosed. Future treatments like BAC have the potential to significantly increase the size of the Vascular Dementia industry. Low-cost, multipurpose products are highly popular and generate a lot of income for the business. The market for dementia care products is anticipated to expand due to trends in consumer acceptance of healthcare products and services. The market for dementia therapeutics and diagnostics is predicted to grow slowly due to the high criteria for clinical studies and drug development. This plays a major role and explains the need to attend Dementia Care 2023.

About Conference

We are extremely glad to promulgate the 15^thInternational Conference on Dementia and Dementia Care, which is slated for November 23-24, 2023 in London,UK.

Dementia Care 2023 is an annual gabfest which glazes the entire range of research in Dementia and Dementia care and shares the various encounters of different treatment methodology and Care Practices. It is the platform for all the innovators, researchers, organizations, scholars, caretakers to discuss and exhibit the recent advancements in the treatment, care and management of Dementia and it also brings together the researchers to dissertate novel drug discovery, technical development in care methods, on-going clinical trials, end of life issues and organizational development.

This conference will provide scope for all the proficient people in the field of Neuroscience and Psychiatry to accomplish their research relationships with each other and to discover global associates for future collaboration.

Who should attend?

Physicians
Geriatricians
Students
Clinical Neurologist
Speech Therapists
Research Faculty
Scientists and professors
Physical Therapists
Nurses
Health Organizations
Social Workers
Persons living with Dementia
Dementia Advocates
Dementia Caretakers
Neurologists
Health Care Analysts
Researchers in field of Neurology
Health care organizations
Geriatric Psychiatrists
All those providing care and treatment to patients with Dementia.

Why to attend?

With members from around the world focused on learning about Dementia and its advances; this is your best opportunity to reach the largest assemblage of participants from the Dementia community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new discoveries in the Dementia treatment and diagnosis, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Dementia Care, treatment, diagnosis are hallmarks of this conference.

For Researchers and Faculty Members:

Speaker Presentations
Poster Display
Symposium hosting (4-5 members team)
Workshop organizing

For Universities, Associations & Societies:

Association Partnering
Collaboration proposals
Academic Partnering
Group Participation

For Students and Research Scholars:

Poster Competition (Winner will get Best Poster Award)
Young Researcher Forum (YRF Award to the best presenter)
Student Attendee
Group registrations

For Business Delegates:

Speaker Presentations
Symposium hosting
Book Launch event
Networking opportunities
Audience participation

For Product Manufacturers:

Exhibitor and Vendor booths
Sponsorship opportunities
Product launch
Workshop organizing
Scientific Partnering
Marketing and Networking with clients

Scientific Sessions

Session 1: Dementia and Aging

Dementia is a term used for the loss of the ability to remember, think, or make decisions that interfere with doing daily tasks. Dementia and age-related memory decline can be distinguished in numerous ways. Neuroscience is not a normal part of ageing, even though it usually affects older adults. Many older adults live their entire lives without ever experiencing Brain Disorders 2023.

Related Conferences: Dementia Conferences | Neuroscience Conferences | Neuroscience Conference | Neurological Disorders Conferences | Neurology Conferences | Neuroscience Meetings | Neuroscience Events | Mental Health Conferences | Neuropsychiatry Conferences | Neurorehabilitation Conferences | Brain Disorders Conferences | Alzheimer’s Conferences | Dementia Conferences | Parkinson Conference | Movement Disorders Congress | Dementia Conferences

Session 2: Lewy Body Dementia

Depositions of the protein alpha-synuclein in neurons cause Lewy body dementia. Hallucinations and rigidity in the movement are symptoms of Lewy body dementia. Disruption of brain cells occurs in Lewy body dementia, and the diagnosis of Lewy body dementia is only possible after a year of observation and progression of symptoms with Parkinson's disease. If cognitive problems emerge within a year of movement abnormalities doctors declare it as Lewy body Dementia; if not, then it is declared as Parkinson Conference.

Session 3: Vascular Dementia

Vascular dementia is caused by a disruption in the brain's blood supply. It usually results in minor stroke and heart problems. There will be certain changes in the brain when the cerebrovascular disease develops in the body and leads to strokes and lesions and resulting alternations in cognition, further addressed at Dementia Care Congress.

Session 4: Frontotemporal Dementia

Frontotemporal Dementia is a broad term used to describe a group of illnesses characterized by progressive nerve cell loss in the frontal and temporal lobes of the brain. Patients with Frontotemporal Dementia lose 70% of their spindle neurons, while other neurons remain unaffected. Frontotemporal Dementia includes changes in behaviour, personality and speech problems. In younger adults, it is a major cause of dementia. Frontal and temporal lobe atrophy may be visible on MRI scans.

Session 5: Semantic Dementia

Semantic dementia is characterized by a gradual loss of the ability to remember the meaning of words, faces, and things as a result of brain shrinkage in the temporal lobes. Over the course of a year, some people exhibit little change, while others change faster. Usually, tracking a person's growth over a year will provide a good indication of how fast they will progress in the future. Join us at Dementia 2023 for more updates.

Session 6: Alzheimer’s disease

Alzheimer's disease is the start of moderate memory loss caused by a loss of capacity to do essential tasks. Alzheimer's disease is a progressive, irreversible Brain Disorder that impairs remembering, wondering, and the ability to execute even the most basic tasks. Family history is the most common risk factor, and many others will be discussed at Dementia Care 2023.

Session 7: Dementia Nursing

Currently, there is no cure for dementia; the focus of the treatment is to slow the progression of dementia and empower people with dementia to live well. To keep their uniqueness, a person with Dementia Care 2023 may brawl. As a result, caregivers must encourage the person with dementia to focus on their goals rather than on what they can no longer accomplish, which will further discussed at Neuroscience 2023.

Session 8: Dementia Care Management

Dementia Care 2023 management has been offered at the homes of dementia patients for six months. It is a model of coordinated care that is also defined as a complicated intervention aimed at providing patients with the best possible treatment and care. Dementia care management has been targeted to the needs of each individual patient and is overseen by six dementia-trained study nurses. Join us at Dementia Care 2023 to learn more.

Session 9: Causes & risk factors for Dementia

Dementia is a degenerative disease; one of the most important risk factors for Dementia is age; people over the age of 65 are more likely to get Dementia. Although age and genetic inheritance from ancestors are uncontrollable, additional risk factors such as hypertension, hyperlipidemia, hyperthyroidism, excessive alcohol consumption, and smoking can be avoided or managed to control Brain Disorders. Dementia can be caused by a head injury, a stroke, or a brain tumour. A healthy lifestyle and correct food can help to prevent a number of risk factors, which will be further addressed at Dementia Care 2023.

Session 10: Dementia Diagnosis

The Mini-Mental State Examination (MMSE), the Mental Score Test, and the Trail Making Test are all tests that can be used to detect dementia. In Vascular Dementia, MRI and CT scans of the brain are used to look for brain tumours and strokes. According to Neuroscience Congress 2023, a dementia diagnosis is frequently deceptive of many conditions such as Parkinson's disease. As a result, the Dementia Society is on the hunt for innovative research procedures and approaches in order to produce more accurate diagnostic tools.

Session 11: Treatment of Dementia

Dementia treatment is determined by the underlying cause. There is no cure for neurodegenerative dementias like Alzheimer's, but there are drugs that can help protect the brain or control symptoms like anxiety and behavioural problems in Neuroscience. Many therapeutic alternatives are being developed as a result of research. A healthy lifestyle, which includes nutritious food, regular exercise, and maintaining social contacts, may minimize the number of persons suffering from dementia and lowers the risk of chronic disease.

Session 12: Bioinformatics approach for Dementia

The advent of Bioinformatics can be used to manage and analyze data generated by today's high-throughput research tools, paving the way for new discoveries in the field of dementia. Epigenomes have been found to have relatively little published data. The data is believed to have come from high-throughput technologies used in human brain screening.

Session 13: Advance Drug for Dementia

There are just a few drugs available to treat dementia, such as cholinesterase inhibitors (Memantine, Galantamine) and n-choline receptor agonists, which are used to treat Alzheimer's disease, dementia, Vascular dementia, as well as Parkinson's disease. Additionally, these medicines will improve cognition. This also includes neuroprotective medications like nimodipine, propentofylline, and posatirelin, which are currently being researched and may be effective in the treatment of Dementia Care.

Session 14: Dementia Awareness

It is critical to raise awareness among dementia-affected families and the general public in order to have a better understanding of how dementia is viewed. If the amount and depth of public awareness of Brain Disorders are not fully recognized, then communication with people to help, educate, and clarify misconceptions will be unsuccessful. Join us at Dementia Care 2023 to learn more.

15th International Conference on
Dementia and Dementia Care

Quick Links

Theme: Dementia: Unraveling the Complexity of Diagnosis to Care